Fundraising Fox

Conexeu Sciences Inc.

NASDAQ: CNXU

Reno, US · Founded 2022 · Nevada corporation · 13 employees on LinkedIn · 1 known investors

Conexeu is developing CXU™, a collagen-based extracellular matrix (ECM) platform for soft-tissue regeneration intended as an alternative to static fillers, combining structural support with tissue in-growth and integration. The platform is positioned as a single formula and device with potential use across a range of human and animal regenerative medicine applications.

BiotechHardwareHealthtechMedical Devices

Founders & leadership

Conexeu Sciences Inc. was founded in 2022 by Mauricio Gonzalez-Ulloa and David Bogart.

MG
Mauricio Gonzalez-UlloaFounder & CEO
DBDavid Bogart
David BogartinChief Commercial Officer, Co-Founder & DirectorFounder of Conexeu Sciences, which is developing CXU™, a collagen-based extracellular matrix platform for soft-tissue regeneration across human and animal regenerative medicine applications.
SD
STEPHEN D INOUYEExecutive
BPBRIAN PILCHER
BRIAN PILCHERExecutive
JSJEFF SHARPE
JEFF SHARPEExecutive
AF
AARON FARBERGExecutive
MHMILES HARRISON
MILES HARRISONinNamed on SEC filing
CCCLAUDIA CHAVEZ-MUNOZ
CLAUDIA CHAVEZ-MUNOZNamed on SEC filing
SPSEBASTIAN PURCELL
SEBASTIAN PURCELLNamed on SEC filing
ACANDREW COSTA
ANDREW COSTANamed on SEC filing
ABAPRIL BURKE
APRIL BURKENamed on SEC filing
ABANA BASTIANI-POSNER
ANA BASTIANI-POSNERNamed on SEC filing

Investors · 1

Innovation UBCVancouver

Reported raises · per SEC filings

Form D private placements

$7.3M disclosed across 14 rounds · 2025–2026

▶$62.7KraisedJul 2026 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DAVID R BOGARTExecutive Officer, Director
  • MILES HARRISONExecutive Officer, Director
  • AARON FARBERGDirector
  • STEPHEN D INOUYEExecutive Officer
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
  • JEFF SHARPEDirector
  • Z PAUL LORENCDirector
  • SEBASTIAN PURCELLDirector
  • BRIAN PILCHERExecutive Officer
  • ANDREW COSTADirector
  • APRIL BURKEDirector
  • ANA BASTIANI-POSNERDirector
Offering amount
$62.7K
Amount sold
$62.7K
First sale
Jul 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$203raisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • APRIL BURKEDirector
  • AARON FARBERGDirector
  • ANA BASTIANI-POSNERDirector
  • MILES HARRISONExecutive Officer, Director
  • SEBASTIAN PURCELLDirector
  • JEFF SHARPEDirector
  • Z PAUL LORENCDirector
  • BRIAN PILCHERExecutive Officer
  • DAVID R BOGARTExecutive Officer, Director
  • STEPHEN D INOUYEExecutive Officer
  • ANDREW COSTADirector
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
Offering amount
$466K
Amount sold
$203
First sale
Jun 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$86.3KraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DAVID R BOGARTExecutive Officer, Director
  • MILES HARRISONExecutive Officer, Director
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
  • STEPHEN D INOUYEExecutive Officer
  • ANA BASTIANI-POSNERDirector
  • SEBASTIAN PURCELLDirector
  • JEFF SHARPEDirector
  • BRIAN PILCHERExecutive Officer
  • ANDREW COSTADirector
  • APRIL BURKEDirector
  • Z PAUL LORENCDirector
  • AARON FARBERGDirector
Offering amount
$86.3K
Amount sold
$86.3K
First sale
Jun 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7KraisedJun 2026 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
  • JEFF SHARPEDirector
  • Z PAUL LORENCDirector
  • STEPHEN D INOUYEExecutive Officer
  • AARON FARBERGDirector
  • MILES HARRISONExecutive Officer, Director
  • BRIAN PILCHERExecutive Officer
  • DAVID R BOGARTDirector
  • SEBASTIAN PURCELLDirector
Offering amount
$2.2K
Amount sold
$1.7K
First sale
Jun 2025
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.9KraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • SEBASTIAN PURCELLDirector
  • MILES HARRISONExecutive Officer, Director
  • STEPHEN D INOUYEExecutive Officer
  • AARON FARBERGDirector
  • Z PAUL LORENCDirector
  • BRIAN PILCHERExecutive Officer
  • JEFF SHARPEDirector
  • DAVID R BOGARTDirector
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
Offering amount
$137.4K
Amount sold
$22.9K
First sale
May 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$44.7KraisedMay 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DAVID R BOGARTDirector
  • SEBASTIAN PURCELLDirector
  • JEFF SHARPEDirector
  • MILES HARRISONExecutive Officer, Director
  • STEPHEN D INOUYEExecutive Officer
  • AARON FARBERGDirector
  • BRIAN PILCHERExecutive Officer
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
  • Z PAUL LORENCDirector
Offering amount
$44.7K
Amount sold
$44.7K
First sale
May 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$543raisedMay 2026 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JEFF SHARPEDirector
  • MILES HARRISONExecutive Officer, Director
  • STEPHEN D INOUYEExecutive Officer
  • SEBASTIAN PURCELLDirector
  • Z PAUL LORENCDirector
  • DAVID R BOGARTDirector
  • BRIAN PILCHERExecutive Officer
  • AARON FARBERGDirector
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
Offering amount
$1.2M
Amount sold
$543
First sale
May 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2026 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JEFF SHARPEDirector
  • Z PAUL LORENCDirector
  • SEBASTIAN PURCELLDirector
  • DAVID R BOGARTDirector
  • STEPHEN D INOUYEExecutive Officer
  • MILES HARRISONExecutive Officer, Director
  • CLAUDIA CHAVEZ-MUNOZExecutive Officer
  • BRIAN PILCHERExecutive Officer
  • AARON FARBERGDirector
Offering amount
$1.8M
Amount sold
$1.8M
First sale
Mar 2026
Incorporated
Corporation, Nevada, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Conexeu Sciences Inc. do?
Conexeu is developing CXU™, a collagen-based extracellular matrix (ECM) platform for soft-tissue regeneration intended as an alternative to static fillers, combining structural support with tissue in-growth and integration. The platform is positioned as a single formula and device with potential use across a range of human and animal regenerative medicine applications.
Who founded Conexeu Sciences Inc.?
Conexeu Sciences Inc. was founded by Mauricio Gonzalez-Ulloa, David Bogart in 2022.
Who are Conexeu Sciences Inc.'s investors?
Conexeu Sciences Inc.'s investors include Innovation UBC.
How much funding has Conexeu Sciences Inc. raised?
Conexeu Sciences Inc. has disclosed $7.3M raised across 14 rounds.
Where is Conexeu Sciences Inc. headquartered?
Conexeu Sciences Inc. is headquartered in Reno, US.